PROTAC EZH2 Degrader-2

Cat. No.: HY-157164

Molecular Formula: $C_{77}H_{93}Cl_2N_{13}O_{12}$

Molecular Weight: 1463.55

Target: PROTACs; Histone Methyltransferase

Pathway: PROTAC; Epigenetics

Storage: 4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 150 mg/mL (102.49 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	0.6833 mL	3.4164 mL	6.8327 mL
	5 mM	0.1367 mL	0.6833 mL	1.3665 mL
	10 mM	0.0683 mL	0.3416 mL	0.6833 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 3.75 mg/mL (2.56 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

PROTAC EZH2 Degrader-2 (compound E-3P-MDM2), an EZH2 inhibitor, is a PROTAC composed of Tazemetostat (EPZ6438) and an E3 ligase system ligand. PROTAC EZH2 Degrader-2 degrades EZH2 in SU-DHL-6 cells in a dose-dependent manner, inhibits the expression of H3K27me3, and simultaneously degrades EED and SUZ12 proteins without affecting their mRNA levels. PROTAC EZH2 Degrader-2 has anti-cancer and anti-proliferative activity[1].

IC_{50} & Target

EZH2[1]

REFERENCES

[1]. Xie H et al. Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma. Bioorg Chem. 2023 Nov;140:106762.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA